Laborie Medical Technologies announced today that it completed the acquisition of drug-coated balloon developer Urotronic. The companies struck an agreement last month for Laborie to buy Urotronic for up to $600 million. Urotronic developed the Optilume DCB used in interventional urology procedures. It treats urethral strictures and benign prostatic hyperplasia (BPH) or enlarged prostate conditions. […]
Urotronic announced that the FDA approved its Optilume BPH catheter system for to alleviate urinary symptoms caused by BPH. Minneapolis-based Urotronic designed Optilume as a minimally invasive surgical therapy. It combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel. This treats lower urinary tract symptoms secondary to BPG (benign prostatic […]
Laborie Medical Technologies announced today that it acquired an exclusive license to the Optilume urethral drug-coated balloon (DCB). Portsmouth, New Hampshire-based Laborie purchased a perpetual, exclusive license to Optilume — developed by Urotronic — following FDA approval in December 2021. The DCB platform received CE mark approval for use in male anterior urethral strictures in […]
Urotronic today announced that it received FDA approval for its Optilume urethral drug-coated balloon for male urethral strictures. Plymouth, Minnesota–based Urotronic designed the paclitaxel-coated balloon to inhibit new scar tissue growth that can occur after endoscopic dilations. Urethral strictures are scars in or around the urethra that can restrict urine flow from the bladder. Get […]
Investments in Medical Alley medtech companies, which had dipped in recent years, have made a comeback, according to the Minnesota trade association. Device companies raised $90 million in the third quarter, pushing the year-to-date total to nearly $200 million raised by 33 companies. Q3’s largest raises in medtech included Urotronic ($26 million, including $20M in Series B funds), 4C Medical ($17 million), […]
Urotronic has raised $20 million in an equity offering involving 7 investors, according to a document filed with the SEC this week. The Minnesota-based company is developing a drug-coated balloon catheter designed to treat urethral strictures in men. Urotronic’s latest fundraising efforts come on the heels of a $6 million offering that closed in July. Get the full story at […]
Urotronic has raised $6.1 million in an equity offering involving 21 investors, according to a document filed with the SEC this week. The Minnesota-based company has not publicly stated how it plans to spend its newly-acquired funds. Urotronic is developing a drug-coated balloon catheter designed to treat urethral strictures in men. Get the full story at our sister […]
Minneapolis-based Urotronic said this week that the FDA approved an investigational device exemption trial for its Optilume drug-coated balloon catheter, which is designed to treat urethral strictures in men. The 200-patient pivotal trial is slated to start enrolling participants immediately. Get the full story at our sister site, Drug Delivery Business News.
Urotronic is launching a feasibility trial of its drug-coated balloon in men with narrowed urethras, according to StarTribune. The Plymouth, Minn.-based company’s Optilume device is inserted into a patient’s urethra and then inflates to dilate the urethra, allowing urine to leave the patient’s bladder. Get the full story at our sister site, Drug Delivery Business News.
The former vice president of R&D for drug-coated balloon maker Lutonix, Christopher Barry, yesterday pleaded guilty to a single count of trade secret theft in federal court in Minneapolis. Barry, who left Lutonix in 2015 to become CEO of Urotronic, admitted to downloading 6 files in April 2015 containing trade secrets about the development of […]